VIKING THERAPEUTICS INC shares surged 35.7% to $40.85 on Tuesday afternoon after its experimental obesity treatment demonstrated durable weight-loss maintenance in a clinical study. The move marked the company's largest one-day percentage gain in over two years. The trial results bolster Viking's strategy to reduce treatment frequency and carve out share in the fast-growing weight-loss sector.

Dosing Flexibility